Skip to Content
MilliporeSigma
  • Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.

Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.

Anticancer research (2018-05-02)
Elise Thoresen Sletten, Marit Arnes, Anne Beate Vereide, Anne Ørbo
ABSTRACT

Progestin therapy has been accepted as therapy for low- and medium-risk endometrial hyperplasia. The aim of this study was to investigate the efficacy of the low-dose levonorgestrel-impregnated intrauterine system (LNG-IUS) 13.5 mg (Jaydess®, Bayer Pharmaceuticals, Berlin, Germany) as therapy for endometrial hyperplasia. A total of 21 women with histologically-verified endometrial hyperplasia were prospectively treated with LNG-IUS Jaydess. Therapy duration was 6 months (n=16) or 3-6 weeks (n=5) depending on individual risk (low- and medium-risk versus high-risk) for co-existent or future endometrial carcinoma. Paired endometrial biopsies were sampled prior to and after therapy and classified according to the WHO94 classification system and D-score. All women with low- and medium risk endometrial hyperplasia had-therapy response. In the group of women with high-risk endometrial hyperplasia only 40% (two out of five) obtained a therapy response. Low-dose LNG-IUS Jaydess was proven to be an excellent therapy option for low- and medium-risk endometrial hyperplasia. For patients with high-risk endometrial hyperplasia hysterectomy or LNG-IUS therapy under close surveillance is advised.

MATERIALS
Product Number
Brand
Product Description

Supelco
ORBO 609 Amberlite XAD®-2 (20/50) 400/200 mg, W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea
Supelco
ORBO 80 Coated Filter, with cassettes unassembled
Supelco
ORBO 402 Tenax® TA specially treated (35/60), 100/50 mg, W,W,W separators, O.D. × L 8 mm × 100 mm, pkg of 50 ea
Supelco
ORBO 49P (OVS) Supelpak-20 specially treated Amberlite XAD®-2 (20/40), 270/140 mg, RC,GFF,F,F (specially cleaned) separators, O.D. × L 13-8 mm × 75 mm , OSHA Versatile Sampler (OVS) Tube, pkg of 10 ea
Supelco
ORBO 554 H2SO4 on Silica Gel (20/40) 150/75 mg, W,W,W separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Supelco
ORBO 53 Activated Silica Gel (20/40) specially cleaned, 400/200 mg with Glass Fiber Filters, GFF,F,F separators, O.D. × L 7 mm × 100 mm, pkg of 50 ea
Supelco
ORBO 502 Activated Silica Gel (20/45) 100/50 mg, W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Supelco
ORBO 23 2-HMP on Amberlite XAD®-2 (20/40), 120/60 mg, W,W,W separators, O.D. × L 6 mm × 85 mm, pkg of 25 ea
Supelco
ORBO 43 Supelpak-20 specially treated Amberlite XAD®-2 (20/40), 100/50 mg, W,W,W (specially treated) separators, O.D. × L 8 mm × 100 mm, pkg of 50 ea
Supelco
ORBO 65P (OVS) Amberlite XAD®-4 specially cleaned, 160/80 mg, RC,GFF,F,F (specially cleaned) separators, O.D. × L 13-8 mm × 75 mm , OSHA Versatile Sampler (OVS), pkg of 10 ea
Supelco
ORBO 90 Carboxen® 564 (20/45), 160/80 mg, W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group MEK (methylethyl ketone)
Supelco
ORBO 24 2-HMP on Amberlite XAD®-2 (20/40), 150/75 mg, W,W,W separators, O.D. × L 6 mm × 105 mm, pkg of 25 ea
Supelco
ORBO 80 Isocyanate Filter, with cassettes: no, filter O.D. 37 mm, pkg of 25 ea
Supelco
ORBO 52 Small Activated Silica Gel (20/40) 150/75 mg, pk 50, W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Supelco
ORBO 92 Carboxen® 564 (20/45), 160/80 mg, W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group Vinyl acetate